Adalimumab in the treatment of refractory non-infectious scleritis: 6-month outcomes

Eye (Lond). 2024 Feb;38(3):628-630. doi: 10.1038/s41433-023-02725-3. Epub 2023 Sep 25.

Authors

Affiliations

¹ Moorfields Eye Hospital NHS Foundation Trust, Uveitis & Scleritis Service, London, United Kingdom.
² Guys & St Thomas' NHS Foundation Trust, Medical Eye Unit, London, United Kingdom.
³ Whittington Health NHS Trust, Rheumatology Department, London, United Kingdom.
⁴ Moorfields Eye Hospital NHS Foundation Trust, Uveitis & Scleritis Service, London, United Kingdom. [email protected].

PMID: 37749373
PMCID: PMC10858275 (available on 2025-02-01)
DOI: 10.1038/s41433-023-02725-3

No abstract available

MeSH terms

Adalimumab / therapeutic use
Humans
Immunosuppressive Agents
Scleritis* / drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha

Substances

Adalimumab
Immunosuppressive Agents
Tumor Necrosis Factor-alpha